Alkem Labs declares ₹43 interim dividend; Q3 FY26 results announced
Alkem Laboratories announced Q3 FY26 results, declaring an interim dividend of ₹43 per share. The record date is February 20, 2026. The company reported consolidated revenue of ₹111,089.5 million and profit after tax of ₹21,000.5 million for the nine months ended December 31, 2025. Standalone revenue was ₹74,054.7 million with a profit after tax of ₹19,680.6 million from continuing operations.
The dividend declaration and financial results are material information for investors, impacting their decisions, but the results themselves do not indicate a significant deviation from expectations that would warrant a high impact.
The declaration of an interim dividend and the announcement of financial results are generally positive indicators for a company.
Alkem Laboratories Limited announced its standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025, following a Board of Directors meeting held on February 13, 2026. The company declared an interim dividend of ₹43 per equity share for the financial year 2025-2026. The record date for this dividend payment has been set as Friday, February 20, 2026, with the payment scheduled to commence on March 6, 2026. The Board meeting commenced at 11:00 a.m. and concluded at 01:45 p.m. The financial results included an exceptional item of ₹527.9 million related to the assessment of the financial impact due to changes in labor regulations following the notification of four Labour Codes by the Government of India, effective November 21, 2025. Additionally, a gain of ₹142.9 million from the sale of the Indore manufacturing facility in the quarter ended June 30, 2025, was classified as an exceptional item in the nine-month results.
For the nine months ended December 31, 2025, Alkem Laboratories reported consolidated revenue from operations of ₹111,089.5 million and a profit after tax of ₹21,000.5 million. Standalone revenue from operations for the same period was ₹74,054.7 million, with a profit after tax of ₹19,680.6 million from continuing operations. The company operates in a single reportable business segment: "Pharmaceuticals". The auditors, Deloitte Haskins & Sells LLP, have issued an unmodified review report on the financial results.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.